When ankle cartilage damage needs surgery

Not always — but the answer depends heavily on the size of the damage and how long it has been there.

The injury in question is called an osteochondral lesion of the talus (OLT): a breach in the cartilage surface, and sometimes the bone beneath it, on the dome of the ankle joint. OLTs are most common in active adults between the ages of 20 and 40, and trauma is the usual trigger — published data suggest they are present in up to 50% of ankle sprains and more than 70% of ankle fractures, though many go undetected at the time of injury.

For smaller, undisplaced lesions caught early, conservative management — a period of offloading, structured physiotherapy, and activity modification — achieves satisfactory results in approximately half of cases. The other half do not settle, and any lesion that is large, cystic, displaced, or has already failed a trial of conservative care will typically need surgery.

Defect size is the single most important factor in deciding which operation is appropriate. Lesions below roughly 150 mm² may respond to reparative techniques such as drilling or microfracture. Above that threshold, reparative options become less reliable, and the clinical pathway shifts towards regenerative procedures designed to restore durable cartilage tissue. Two techniques occupy this space for the ankle: OATS and ACI. The sections that follow explain what each involves and which patients are most likely to benefit.

OATS for talar defects — what it delivers and where it has limits

For small, well-contained lesions with an intact knee donor site, OATS remains one of the most dependable single-stage options available.

The procedure transfers one or more cylindrical osteochondral plugs — bone with its native hyaline cartilage cap intact — from a low-load region of the ipsilateral knee to the prepared talar defect. The cartilage is living and structurally complete from day one, which is the key advantage: there is no waiting period for tissue to mature, and the mechanical restoration is immediate.

The outcome data are persuasive for appropriately selected patients. Zengerink et al.'s 2009 systematic review of 243 talar cases reported an overall success rate of 87%, with certain individual series reaching 100% — a benchmark that few surgical techniques at the ankle can match when patient selection is right.

The documented limitations, however, are specific to the ankle environment. Talar cartilage has a lower water content and a higher glycosaminoglycan concentration than knee cartilage, meaning knee-derived plugs carry different mechanical properties from the tissue they are replacing. Separately, the talar dome is convex, whereas the corresponding knee donor surfaces are comparatively flat; plugs that fit well at harvest may create subtle geometric incongruencies at the implant site, raising concern about edge-loading over time. Donor-site morbidity at the knee and a practical ceiling on resurfaceable area add further constraints for larger defects.

These limitations do not undermine OATS for smaller lesions — but they define the clinical gap that ACI is specifically designed to address.

How ACI works at the ankle

The two-stage design is deliberate, and understanding why helps explain both the procedure's strengths and its longer overall timeline compared with OATS.

Stage 1 is a short arthroscopic procedure in which the surgeon harvests a small cartilage biopsy — typically 200–300 mg — from the superomedial margin of the femoral trochlea, a low-load region of the knee that tolerates the sampling well. The tissue is preserved at 4°C and sent to a specialist cell laboratory, where the chondrocytes are isolated and expanded in culture over several weeks.

Stage 2 is the implantation. The prepared talar defect is cleared of any sclerotic bone before the cultured cells — mixed with bone-marrow-derived mesenchymal stem cells to support integration — are placed onto a collagen scaffold shaped precisely to the defect. In modern matrix-based variants, collectively called MACI, the chondrocytes are pre-seeded onto the scaffold membrane before surgery rather than being injected beneath a periosteal patch as in first-generation ACI; this reduces some of the technical complexity of the original technique without changing the underlying biological principle.

Where the talar lesion sits in a position that cannot be reached through a straightforward ankle approach — as is often the case with medially placed defects — the surgeon may perform a malleolar osteotomy to gain adequate access. This is a positional requirement driven by ankle geometry, not a complication of the procedure itself.

Biologically, the distinction from OATS is important: ACI regenerates hyaline-like cartilage within the ankle's own joint environment rather than transplanting mechanically mismatched tissue from the knee. Because the cell volume can be expanded during culture, there is no practical size ceiling — the same process that repairs a 2 cm² defect can be scaled to resurface a much larger or irregularly shaped area.

Who ACI is right for

Four factors point most reliably towards ACI candidacy, and understanding them helps patients arrive at a consultation with the right questions.

Defect size is the primary criterion. Lesions above 150 mm² are generally too large to be resurfaced adequately by OATS plugs or to heal durably after marrow stimulation alone; the cell expansion step in ACI removes that size ceiling entirely, making it the preferred option when the defect area is substantial.

Prior failed repair is the second common pathway in. Patients who have undergone microfracture, drilling, or debridement that has not held — leaving persistent pain, mechanical symptoms, or MRI evidence of deterioration — are strong ACI candidates. Prior marrow-stimulation procedures are less likely to compromise ACI performance than they are for some other regenerative options, which is a meaningful distinction for patients who have already been through one operation.

Knee donor-site status also influences the decision. Where the knee already has its own cartilage concerns, or the patient's sport or occupation places high demand on both lower limbs, avoiding a structural osteochondral harvest from that joint is clinically sensible. ACI's Stage 1 biopsy — approximately 200–300 mg from a low-load area — carries a much smaller cost to the donor site than harvesting full plugs for transplantation.

Cystic lesions, where damage has extended into the subchondral bone, typically require bone grafting at Stage 1 before ACI implantation at Stage 2.

Beyond the lesion itself, age, activity demands, and a realistic commitment to the post-operative rehabilitation programme all form part of the assessment. Whether ACI is appropriate in any individual case is confirmed by a consultant review — including MRI and often weight-bearing imaging — rather than defect size alone.

ACI versus OATS — how the choice is made

The clinical choice rests on lesion size, prior surgical history, and the status of the knee donor site — three variables that, taken together, usually point clearly in one direction without the techniques needing to compete with each other.

Below roughly 150 mm² — a defect area that can realistically be covered by one or two osteochondral plugs — OATS is generally preferred. It is single-stage, delivers native hyaline cartilage immediately, and carries a strong evidence base, including the 87% success rate reported by Zengerink et al. (2009) across 243 talar cases. For a first-presentation lesion in this size range with an accessible knee donor site, the two-stage commitment of ACI is difficult to justify.

Above that threshold, or when the knee donor site cannot be used, ACI becomes the more appropriate choice. The size ceiling that constrains plug-based transfer does not apply; the cell expansion step means the same process can resurface a large or irregularly shaped area. ACI also sidesteps the biomechanical and geometric mismatch inherent in transferring knee-derived plugs to the talar dome — a consideration that grows more meaningful as defect size increases and edge-loading becomes a greater concern.

Lesions that have failed prior reparative surgery — microfracture, drilling, or debridement — similarly favour ACI, which can address residual damage without being compromised by that surgical history in the way some other techniques are.

AMIC (autologous matrix-induced chondrogenesis) occupies its own lane rather than sitting between two superior alternatives. For intermediate-sized lesions, or in centres where cell-culture infrastructure is not accessible, it offers a one-stage matrix-augmented option. Published outcome data from Weigelt et al. (2019), covering 2–8-year follow-up in talar lesions, support its standing as a legitimate pathway in its own right.

Direct head-to-head trial evidence comparing ACI and OATS specifically at the talus remains limited; the comparative picture comes primarily from systematic reviews and case series. The decision, in practice, follows consultant-led assessment — including MRI review and lesion staging — rather than size thresholds applied in isolation.

Recovery, outcomes, and realistic expectations

Recovery timelines diverge sharply between the two procedures.

After OATS — a single-stage operation — progressive weight-bearing typically resumes within weeks, with return to sport measured in a few months depending on defect size and graft stability. ACI involves two separate procedures separated by the cell-culture interval, making the cumulative timeline substantially longer. Weight-bearing after Stage 2 is introduced gradually, and the regenerated tissue requires time to mature and integrate before full activity is safe. Patients who accept this from the outset tend to sustain the rehabilitation programme more consistently.

On outcomes, the evidence base is stronger for OATS than for ankle ACI. The Zengerink et al. (2009) figure of 87% across 243 talar cases — noted in the earlier section — is a well-established aggregate result. Long-term ACI data are more mature in the knee: Minas et al. (2014) reported minimum 10-year follow-up in that setting. Ankle-specific ACI functional scores from large prospective series remain sparse in the published literature — a genuine field-level evidence gap that reflects the relative rarity of the procedure rather than evidence of poor outcomes.

ACI is also structurally demanding regardless of where it is performed: two procedures, specialist cell-culture infrastructure, and an extended physiotherapy commitment are inherent to the pathway.

The practical distinction between the two techniques comes down to this: OATS resolves smaller, well-contained lesions efficiently in one stage; ACI addresses larger, cystic, or previously failed lesions where plug transfer would be geometrically mismatched or insufficient in coverage. Both are joint-preservation procedures designed for a young, active population — the choice between them is about matching the right tool to the lesion, not about one technique replacing the other.

1. [1] Autologous chondrocyte implantation – Wikipedia. https://en.wikipedia.org/?curid=19074150 https://en.wikipedia.org/?curid=19074150